Certification for CME credit requested
We’re bringing together scientists, clinicians, and innovators from diagnostic and pharma industries as well as academia around the world for a one-day deep dive into one of the most fascinating emerging topics in neuroscience and medicine: the Brain-Nose Interface (BNI).
We are exploring the direct link between the nose and the brain – with exciting implications for diagnostics, therapeutics and interdisciplinary science.
Join us in Munich for an inspiring day of panel talks, discussion, and community building.
Date:
November 21, 2025
Location:
Hotel Maria’s Platzl, Munich, Germany
What to Expect:
- Interdisciplinary Program – Explore groundbreaking work at the intersection of:
- Anatomy & Physiology of the Brain-Nose Interface
- Brain Biomarkers in Research and Clinical Use
- Opportunities of the Brain-Nose Interface
- Expert Speakers – A carefully selected group of international thought leaders (view speaker highlights below)
- Community First – Meet fellow researchers, clinicians, and industry partners passionate about advancing the BNI
The detailed event program can be found below.
Why BNI, Why Now?
The brain-nose interface plays a pivotal role in neurology, diagnostics, and therapeutic innovation and could have tremendous potential to improve the healthcare industry. Yet it remains underexplored. Our mission is to:
- Spark a lasting interdisciplinary dialogue
- Lay the groundwork for future research collaborations
- Raise awareness and visibility for this emerging field
Let’s shape the future of the BNI field, together.
Coming Soon! Stay Tuned for:
- Accommodation & travel details
- Sponsor and partner announcements
Questions?
Feel free to contact us at events@noselab.com.
Join us! Register Now and Become a Part of the BNI Community:
Event Program
Thursday, November 20
1:00 – 5:00 p.m.
Pre-Symposium Lab Tour & Poster Discussion (For registered participants only)
Participants are invited to visit the BNI laboratories for a guided tour and scientific poster discussion. This informal pre-symposium gathering provides an opportunity for early networking and direct dialogue with researchers. Registration is required via email at events@noselab.com
Friday, November 21
8:30 a.m.
Registration
9:00 a.m.
Opening Remarks
Dr. Peter Fruhstorfer, CEO Noselab GmbH
9:15 a.m.
The Clinician’s Perspective:
Current Diagnostic Approaches And Unmet Needs In Brain Pathology
Prof. Dr. Oliver Peters, Head of Department of Psychiatry at Klinikum F rankfurt (Oder) and Senior Physician at the Department of Psychiatry and Psychotherapy at Charité – Universitätsmedizin Berlin
Prof. Dr. Oliver Peters
Dr. Peters is a trained psychiatrist who serves as the head of the Department of Psychiatry at Klinikum Frankfurt (Oder). He continues his scientific research at the Department of Psychiatry and Psychotherapy at Charité, where he was W2 professor for geriatric psychiatry from 2019 to 2023.
His clinical and research work focuses on the early detection, prevention, and treatment of cognitive disorders and dementias, including Alzheimer’s disease. He has led memory and dementia prevention programs at Charité and continues to advance diagnostic and therapeutic approaches through neuropsychology, imaging, and biomarker research.
9:40 a.m.
SESSION 1: The Brain-Nose Interface
Chair: Dr. Peter Kaspar
09:50 a.m.
Pathways Of Communication Between The Brain And The Nose
Prof. Dr. Roxana Carare, Professor of Clinical Neuroanatomy, University of Southampton & Nour Abdul-Karim Gharaibeh, PhD Student
Prof. Dr. Roxana Carare
Prof. Dr. Roxana Carare was born and educated in Romania, where she earned her medical degree from the University of Medicine and Pharmacy “Carol Davila” in Bucharest. Later, she moved to the United Kingdom to pursue her academic career and obtained a PhD in experimental neuropathology from the University of Southampton.
She currently serves as Professor of Clinical Neuroanatomy at the University of Southampton, where she leads the Carare Research Group. Her work focuses on how the brain clears waste products, particularly the movement of amyloid-β along blood vessel walls, and how failure of these clearance pathways contributes to conditions such as Alzheimer‘s disease and cerebral amyloid angiopathy.
10:10 a.m.
Neuropathological Comparisons Of Olfactory Epithelium Versus Brain In Patients With Parkinson’s, Dementia And COVID-19
Prof. Dr. Michael Schlossmacher, Director of Neuroscience and Neurology, University of Ottawa
Dr. Michael Schlossmacher
Dr. Michael Schlossmacher grew up in Vienna, Austria and completed his training as a clinician-scientist in Boston, Massachusetts. He currently serves as the Director of the Neuroscience Program at the Ottawa Hospital Research Institute and is a Full Professor at the University of Ottawa in Canada’s capital. As a neurologist he works with Movement Disorder patients.
He holds the Bhargava Family Research Chair in Neurodegeneration at The Ottawa Hospital and recently co-founded a small company, NeuroScent Solutions. Its objective is to facilitate home-based screening for Parkinson disease with a simple questionnaire, an 8-scent-based NeuroScent Card® and an app that generates a risk score report.
10:30 a.m.
Olfactory Bulb Neuropathologies In Neurodegenerative Disorders
Dr. Cécilia Tremblay, Postdoctoral Fellow at Douglas Research Center and McGill University
Dr. Cecilia Tremblay
Dr. Cécilia Tremblay, PhD, holds a bachelor’s degree in medical biology and performed her graduate studies in biomedical sciences (Master) and neuroscience (Doctorate) at the University of Quebec at Trois-Rivières and the University of Montreal. She completed her first postdoctoral fellowship at Banner Sun Health Research Institute (Arizona, USA) in the Civin laboratory for neuropathology.
She is currently a postdoctoral fellow at McGill university (Montreal, Canada). She was first awarded a Quebec’s research funds and a Canadian Institute of health Research postdoctoral scholarship.
Her research focuses on olfactory neurosciences and neuropathology of aging and neurodegenerative diseases and aims to help early disease diagnosis, biomarker detection and validation as well as disease profiling.
10:50 a.m.
Discussion – Q&A
11:10 a.m.
Coffee Break & Networking
11:40 a.m.
SESSION 2: Analytical Proteomics
Chair: Dr. Peter Kaspar
11:50 a.m.
Analytical And Technical Challenges In The Study Of Brain Biomarkers
Prof. Dr. Dr. Manfred Uhr, Head of Clinical Laboratory and Core Unit at the Max Planck Institute, Psychiatry
12:10 p.m.
Mass Spectrometry In Proteomics:
Opportunities And Frontiers
Dr. Stephan Müller, Research Fellow, German Center for Neurodegenerative Diseases (DZNE)
12:30 p.m.
Proteomic Profiling Of Nasal Secretion:
Translational Insights
Dr. Philipp Geyer, Founder, CSO and Managing Director ions.bio
Dr. Philipp Geyer
Dr. Philipp E. Geyer is a proteomics expert based in Germany and co-founder and managing director of ions.bio GmbH. He previously co-founded OmicEra Diagnostics GmbH. Dr. Geyer’s research centers on mass spectrometry-based biomarker discovery. He completed his PhD at the Max Planck Institute of Biochemistry and the Novo Nordisk Foundation Center for Protein Research in Copenhagen.
His work has significantly advanced clinical proteomics applications for health and disease assessment.
Dr. Geyer is also an active member of the Plasma Proteomics Committee at HUPO.
12:50 p.m.
Discussion – Q&A
1:10 p.m.
Networking Lunch
2:10 p.m.
SESSION 3: Clinical Opportunities
Chair: Dr. Peter Kaspar
2:20 p.m.
When Words Can No Longer Reach, And Music Becomes The Final Bridge:
Music Therapy In Dementia
Prof. Dr. Jens Wiltfang, Professor and Head of Department of Psychiatry and Psychotherapy at the University Medical Center Göttingen (UMG) & Shogher Hoveyan, Pianist
Prof. Dr. med. Jens Wiltfang
Prof. Dr. Jens Wiltfang studied medicine at the Hannover Medical School, where he obtained his medical degree. He completed his specialist medical training in psychiatry, psychotherapy, and neurology at the University Medical Center Göttingen, where he also earned his habilitation in psychiatry and psychotherapy in 2002.
He is currently Professor and Head of the Department of Psychiatry and Psychotherapy at the Universitätsmedizin Göttingen and the coordinator of Clinical Research at the German Center for Neurodegenerative Diseases, Satellite Göttingen (DZNE). His work centers on early and predictive biomarker-based diagnosis of neurodegenerative diseases, such as Alzheimer’s, and the translational neurobiology of dementia.
3:05 p.m.
Nose-To-Brain Drug Delivery:
A Personal Perspective On Translating Innovation Into Therapy
Dr. Iris Shichor, CEO BioChange LTD
Dr. Iris Shichor
Dr. Iris Shichor earned her Ph.D. in Biochemistry and Physiology from the Hebrew University of Jerusalem and completed a postdoctoral fellowship in the laboratory of Prof. Robert Langer at the Harvard-MIT Division of Health Sciences and Technology, where she focused on controlled-release local anesthetic formulations. She brings extensive expertise in neuroscience, biochemistry, and drug-delivery systems, with a career dedicated to translating scientific innovation into practical healthcare solutions.
Before co-founding and leading SipNose Ltd., a Direct Nose-to-Brain delivey platform company, Dr. Shichor served as VP of R&D at ClearFarma and as a Senior Scientist and Project Leader at NanoCyte Ltd., where she developed a novel platform for transdermal delivery.
She now serves as CEO of BioChange Ltd., a biotechnology company developing tissue-regeneration technologies, where she continues to drive the advancement of next-generation biomedical products from concept to clinical application.
3:25 p.m.
Company Spotlight:
Noselab – Vision, Approach & Opportunities
Dr. Peter Fruhstorfer, CEO Noselab GmbH
3:45 p.m.
Discussion
4:15 p.m.
Closing Remarks & Acknowledgements
About Noselab GmbH:
Noselab GmbH is a leading innovator in diagnostic breakthrough technology, specializing in the early detection and management of neurodegenerative diseases. Leveraging its revolutionary diagnostic platform, which analyzes nasal Cerebro-Spinal Fluid (CSF) biomarkers, Noselab aims to transform disease diagnosis, staging, and therapy monitoring to improve patient outcomes. As a member of the Munich Bio-M cluster, Noselab collaborates with leading experts and institutions to drive innovation and foster collaboration in biomedical research and development.
Legal Disclaimer:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to, the risks and uncertainties associated with the development of diagnostic technologies, the success of clinical trials, the regulatory approval process, market acceptance of products, competition, intellectual property rights, and other risks inherent in the diagnostic development industry.
Additionally, any statements regarding future performance, achievements, or financial outlook of the Company are forward-looking statements and are subject to risks and uncertainties. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.
Investors and potential investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement.